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First Pharmacy Outreach Meeting
The Iowa Board of Pharmacy held its first Pharmacy Outreach 
Meeting on Tuesday evening, September 13, 2011, at the Blank Park 
Zoo in Des Moines, IA. Approximately 100 pharmacists and 50 
pharmacy technicians attended and made the meeting a success. The 
program included a review of new laws and administrative rules, as 
well as a discussion of current pharmacy projects and study groups. 
A “town hall” meeting was also held to allow participants to provide 
input to the Board on topics of concern. The next Pharmacy Outreach 
Meeting will be held at the Amana Clarion Inn in Williamsburg, IA, 
on Thursday evening, 
November 10. A 
Pharmacy Outreach 
breakfast meeting is 
planned for Sunday 
morning, January 22, 
2012, at the Marriott 
Hotel in downtown 
Des Moines. It will be 
held during the Iowa 
Pharmacy Associa-
tion (IPA) Expo.
New Laws
Pharmacy Pilot Projects
New legislation permits the Board to allow pharmacy “pilot 
projects.” The Board may only consider projects that expand 
pharmaceutical care services that contribute to positive patient 
outcomes. The Board may not consider any project intended only 
to provide a competitive advantage. In addition, pilot projects may 
not expand the definition of the practice of pharmacy. Projects will 
be approved for a specified period of time and may not exceed 18 
months. New administrative rules will identify the procedures for 
applying for approval of pilot or demonstration research projects. 
The Board will review all applications and either approve or deny 
them. The pharmacist who is responsible for any approved project 
must file a written summary of the project results with the Board 
within three months after the completion of the project. The Board 
must submit reports to the legislature.
Iowa Prescription Monitoring Program
The two-year sunset provision has been removed and the pre-
scription monitoring program (PMP) is now permanent. There was 
a change made in the PMP law to allow an “agent” of a practitioner 
to register and request information from the PMP. New adminis-
trative rules will identify the qualifications for a pharmacist’s or 
prescribing practitioner’s agent and will limit the number of agents 
to whom PMP access may be delegated.
Epilepsy Drugs
New legislation has created a task force of patients, physicians, 
and pharmacists to provide education and information on epilepsy 
drugs. The task force will also assess the impact on patients of the 
use of generic antiepileptic drugs to treat epileptic seizures. The 
task force will be composed of three patients appointed by the Epi-
lepsy Foundation of Iowa; three physicians appointed by the Iowa 
Medical Society and the Iowa Osteopathic Medical Association; 
and three pharmacists appointed by the IPA. The task force shall 
submit a report of its activities, findings, and recommendations to 
the legislature by January 1, 2013.
Drug Disposal Take-Away Program
New legislation allows the Board to provide annual funding for 
the administration of the pharmaceutical collection and disposal 
program – the TakeAwaytm Environmental Return System – that 
was established in 2009. The Board may allocate up to $125,000 
of its license fees per year for this purpose. The program provides Participants gather for the first Board of 
Pharmacy Outreach Meeting.
Back Row from Left: Peggy Whitworth, public member; DeeAnn 
Wedemeyer-Oleson, pharmacist member; and Sue Frey, chair. Front 
Row from Left: Mark Anliker, pharmacist member; Ed Maier, vice 
chair; Lloyd Jessen, executive director; and Jim Miller, pharmacist 
member. Not pictured: LaDonna Gratias, public member.
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labeling of over-the-counter (OTC) liquid drug products to minimize 
the risk of accidental overdoses (www.fda.gov/Drugs/DrugSafety/
MedicationErrors/ucm253715.htm). Unfortunately, the guidance still 
mentions both TEAspoon and TABLEspoon. The Consumer Healthcare 
Products Association has also published guidelines (www.chpa-info 
.org/scienceregulatory/Voluntary_Codes.aspx#volumetricmeasure) to 
improve the format for volume measures within the dosing directions 
for OTC products. The abbreviation “mL” is recommended for use 
on accompanying dosing devices that measure OTC oral liquid drug 
products so they match the dosing directions in labeling for children. 
The group has also told companies to avoid directions that mention 
tablespoon, cubic centimeters (cc), dram, fluid ounce (Fl Oz), and 
dropper(ful), and to use mL as the sole unit of measure in the dosing 
directions or, alternatively, mL and the “TEAspoonful” equivalent (eg, 
5 mL (1 TEAspoon)). 
While these are excellent moves to improve safety, ISMP would 
like to see the complete elimination of TEAspoonful amounts and the 
abbreviation “tsp.” Doses expressed using mL alone would be the best 
way to eliminate the risk of mix-ups. The ISMP board fully supports 
this initiative and is currently in the process of approving a formal ISMP 
position on this issue. ISMP hopes the health care industry will also 
support this initiative. 
‘Know Your Dose’ Campaign Aims to Prevent 
Acetaminophen Overdose
The Acetaminophen Awareness Coalition, has launched www 
.KnowYourDose.org, a Web site aimed to educate consumers about the 
dangers of acetaminophen overdose and how to ensure that the correct, 
safe dosage is administered. “Know Your Dose” stresses to patients 
the importance of checking the labels of both prescription and over-
the-counter medications for the amount of acetaminophen contained in 
order to ensure that they do not exceed recommended maximum dosage 
levels. Health care providers may order a free Know Your Dose kit that 
includes materials to help educate patients about safely using medica-
tions containing acetaminophen. The kit includes posters, information 
cards for patients, and a display holder for use in distributing the cards. 
Members of the Acetaminophen Awareness Coalition include Alli-
ance for Aging Research, American Academy of Nurse Practitioners, 
American Academy of Physician Assistants, American Pain Foundation, 
American Pharmacists Association, CHPA Educational Foundation, 
National Association of Boards of Pharmacy® (NABP®), National 
Association of Chain Drug Stores, National Community Pharmacists 
Association, National Consumers League, and the National Council on 
Patient Information and Education. The campaign was developed under 
advisement from the American Academy of Pediatrics, CDC, and FDA.
Methylene Blue and Linezolid May Interact With 
Certain Psychiatric Medications
FDA has issued two safety communications regarding adverse drug 
reactions in patients taking certain psychiatric medications, and also 
given methylene blue or linezolid (Zyvox®). Specifically, FDA has 
received reports of serious central nervous system reactions in patients 
taking serotonergic psychiatric medications who are also given methy-
lene blue, a product commonly used in diagnostic procedures. FDA 
explains that “[a]lthough the exact mechanism of this drug interaction 
is unknown, methylene blue inhibits the action of monoamine oxidase 
A – an enzyme responsible for breaking down serotonin in the brain. It 
is believed that when methylene blue is given to patients taking seroto-
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2011-2012 Influenza Vaccines Approved by FDA 
Food and Drug Administration (FDA) announced that it has approved 
the 2011-2012 influenza vaccine formulation for all six manufacturers 
licensed to produce and distribute influenza vaccine for the United 
States. The vaccine formulation protects against the three virus strains 
that surveillance indicates will be most common during the upcoming 
season and includes the same virus strains used for the 2010-2011 in-
fluenza season. The Centers for Disease Control and Prevention (CDC) 
Advisory Committee on Immunization Practices (ACIP) recommends 
that everyone six months of age and older receive an annual influenza 
vaccination. Details about the new vaccines are available in an FDA news 
release at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm263319.htm, and information about the ACIP recommendations are 
available on the CDC Web site at www.cdc.gov/media/pressrel/2010/
r100224.htm.
Another TEAspoon – mL Mix-Up 
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency that 
analyzes medication errors, near misses, and 
potentially hazardous conditions as reported 
by pharmacists and other practitioners. ISMP then makes appropriate 
contacts with companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To read about 
the risk reduction strategies that you can put into practice today, sub-
scribe to ISMP Medication Safety Alert!® Community/Ambulatory Care 
Edition by visiting www.ismp.org. ISMP is a federally certified patient 
safety organization, providing legal protection and confidentiality for 
submitted patient safety data and error reports. ISMP is also an FDA 
MedWatch partner. Call 1-800/FAIL-SAF(E) to report medication errors 
to the ISMP Medication Errors Reporting Program or report online at 
www.ismp.org. ISMP address: 200 Lakeside Dr, Suite 200, Horsham, 
PA 19044. Phone: 215/947-7797. E-mail: ismpinfo@ismp.org.
A few weeks ago ISMP heard from a mother whose child was ac-
cidentally given an overdose of an antibiotic. A pharmacist accidentally 
provided instructions on the prescription label for her child to receive 
3.5 TEAspoonfuls of a liquid antibiotic for 10 days instead of 3.5 mL. 
The medication was dispensed in a 60 mL bottle. The child was given 
3.5 TEAspoonfuls each day for three days. By the fourth day only one 
TEAspoonful (5 mL) was left in the bottle, so the mother called the 
pharmacy and learned that the dosage amount on the label was incorrect. 
The child experienced bouts of diarrhea and a yeast and fungal infection 
in the vaginal area. 
Mix-ups between teaspoons and mL are common and have been hap-
pening for many years. ISMP first mentioned the problem in its June 28, 
2000 newsletter article, “Oral liquid medications may be more vulner-
able to errors than previously recognized” (www.ismp.org/Newsletters/
acutecare/articles/20000628_2.asp). ISMP has received more than 50 
similar errors in recent years, most resulting in patient harm. It is time 
to standardize to a single way of measuring liquid medications, using 
the metric system with volumes expressed in mL. If we all used the 
metric measurement when prescribing, dispensing, and administering 
medications, these types of mix-ups would no longer happen. 
In response to ongoing errors, in June 2009, ISMP called for elimi-
nation of TEAspoonful and other non-metric measurements to prevent 
errors (www.ismp.org/pressroom/PR20090603.pdf). In May 2011, FDA 
published a guidance suggesting ways for manufacturers to improve the 
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nergic psychiatric medications, high levels of serotonin can build up in 
the brain, causing toxicity. This is referred to as Serotonin Syndrome. 
Signs and symptoms of Serotonin Syndrome include mental changes 
(confusion, hyperactivity, memory problems), muscle twitching, exces-
sive sweating, shivering or shaking, diarrhea, trouble with coordination, 
and/or fever.” FDA has published a list of the serotonergic psychiatric 
medications that can interact with methylene blue, available at www.fda 
.gov/Drugs/DrugSafety/ucm263190.htm#table, and advises that “Methy-
lene blue should generally not be given to patients taking serotonergic 
drugs.” Exceptions and more information for health care providers and 
patients are available in an FDA Drug Safety Communication available 
at www.fda.gov/Drugs/DrugSafety/ucm263190.htm. 
Similar reports of interactions between certain serotonergic psychiat-
ric medications and the antibacterial drug, linezolid (Zyvox) have also 
been reported to FDA. FDA has published a list of the serotonergic 
psychiatric medications that can interact with linezolid, available at 
www.fda.gov/Drugs/DrugSafety/ucm265305.htm#table, and advises that 
“Linezolid should generally not be given to patients taking serotonergic 
drugs.” Exceptions and more information about the linezolid interaction 
for health care providers and for patients are available in an FDA Drug 
Safety Communication available at www.fda.gov/Drugs/DrugSafety/
ucm265305.htm.
NABP Looking For Item Writers to Develop New 
Questions for NAPLEX, MPJE, FPGEE, and PCOA
NABP is seeking individuals to serve as item writers for the North 
American Pharmacist Licensure Examination® (NAPLEX®), Multistate 
Pharmacy Jurisprudence Examination® (MPJE®), the Foreign Pharmacy 
Graduate Equivalency Examination® (FPGEE®), and the Pharmacy 
Curriculum Outcomes Assessment® (PCOA®).
Pharmacists in all areas of practice and faculty from schools and 
colleges of pharmacy are encouraged to apply. To be considered as an 
item writer for the NAPLEX and MPJE, pharmacists must have at least 
two years of pharmacy practice experience.
Item writers will be selected based on the specific needs of the 
programs. Those who are chosen will be asked to attend a workshop at 
NABP Headquarters with travel, lodging, and ancillary expenses paid 
by NABP. 
Attendees will receive detailed instructions and training materials 
describing the item-writing process and content-related requirements for 
their designated examination. Item writers will then be asked to develop 
new test items that will be considered for inclusion in NABP licensure 
and certification and assessment examination programs.  
The NAPLEX is an examination consisting of 185 selected-response 
and constructed-response test questions, the majority of which are asked 
in a scenario-based format, that covers important information about the 
knowledge, judgment, and skills an entry-level pharmacist is expected 
to demonstrate. The three competency areas of the examination are: 
 ♦ Assess pharmacotherapy to ensure safe and effective therapeutic 
outcomes
 ♦ Assess safe and accurate preparation and dispensing of medications 
 ♦ Assess, recommend, and provide health care information that pro-
motes public health
The MPJE is a computer-based examination that consists of 90 select-
response items. It combines federal and state-specific questions that test 
the pharmacy jurisprudence knowledge of prospective pharmacists on 
the following areas:
 ♦ Legal aspects of pharmacy practice, including responsibilities with 
regard to the distribution and dispensing of pharmaceuticals and for 
the care of patients
 ♦ Licensure, registration, certification, and operational requirements
 ♦ Regulatory structure and terms of the laws and rules that regulate 
or affect pharmacists, pharmacies, manufacturers, and distributors
The FPGEE is a comprehensive examination consisting of 250 mul-
tiple-choice questions that measures four major pharmacy content areas: 
 ♦ Basic biomedical sciences
 ♦ Pharmaceutical sciences
 ♦ Social/behavioral/administrative pharmacy sciences 
 ♦ Clinical sciences
The PCOA is a 220-question, multiple-choice assessment that is 
administered to pharmacy students in all four professional years. The 
assessment follows a blueprint that reflects actual curriculum hours 
established through a national sample of PharmD programs in the US 
and is broken down into the following four areas:
 ♦ Basic biomedical sciences
 ♦ Pharmaceutical sciences
 ♦ Social, behavioral, and administrative pharmacy sciences
 ♦ Clinical sciences
Interested individuals should mail or fax a letter of interest indicating 
their current practice/educational setting, specialties/certifications, and 
years of experience, along with a resume or curriculum vitae via mail 
to NABP Executive Director/Secretary Carmen A. Catizone at 1600 
Feehanville Drive, Mount Prospect, IL 60056; via e-mail at exec-office@
nabp.net; or via fax at 847/391-4502. 
Please note, applications are accepted on a continuous basis and 
kept on file for a period of five years. For more information about item 
writing, contact NABP at custserv@nabp.net.
Clarification Regarding Pradaxa Storage and 
Handling Requirements
An FDA alert released in March 2011 details important storage and 
handling guidelines for Pradaxa® (dabigatran etexilate mesylate) cap-
sules, as reported in the third quarter NABP National Pharmacy Compli-
ance News. As a point of clarification, the FDA-approved Pradaxa label 
states that once opened, the product must be used within 30 days. FDA 
is currently reviewing data that indicate no significant loss of potency 
up to 60 days after the bottle is opened as long as Pradaxa is stored in 
the original bottle and the handling requirements are met. An FDA Drug 
Safety Communication available at www.fda.gov/Safety/MedWatch/
SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249005 
.htm provides more details, and the manufacturer’s Pradaxa safety 
information is available at www.pradaxa.com by clicking on the link 
for “Important Storage & Handling Information” at the top of the page. 
NABP E-News – Sign Up for Free Today!
NABP e-News is a free weekly electronic newsletter that deliv-
ers up-to-date information on policy issues and pharmacy practice 
standards directly to your e-mail.
To subscribe, visit the Newsroom on the NABP Web site at 
www.nabp.net/news/ and click the subscribe button located along 
the top right of the page titled “Sign Up to Receive NABP E-News.” 
Questions? Contact custserv@nabp.net.
National Association of Boards of Pharmacy Foundation, Inc
1600 Feehanville Drive
Mount Prospect, IL 60056
IOWA BOARD OF PHARMACY
Presorted Standard
U.S. Postage
PAID
Chicago, Illinois
Permit No. 5744
for the management and disposal of unused, excess, and expired 
pharmaceuticals.
New, Revised, and Proposed Administrative 
Rules
For detailed information about rule changes, please visit the 
Board’s Web site at www.legis.state.ia.us/aspx/ACODocs/chapterL-
ist.aspx?agency=657. 
 ♦ Continuing Pharmacy Education 
657 IAC Subrule 2.12: Two hours of continuing education (CE) 
are now required in both pharmacy law and medication safety 
every two years.
 ♦ Patient Counseling
657 IAC Rule 6.14: Pharmacist counseling is required whenever 
changes to a patient’s drug therapy occur.
 ♦ Hospital Pharmacy
657 IAC Rule 7.1: The definition of “hospital pharmacy” has 
been expanded to include animal patients; verbal orders for 
drug administration have been clarified.
 ♦ Pharmacy Closings
657 IAC Subrule 8.35(7): Thirty-day notification is now re-
quired for the Board, Drug Enforcement Administration, and 
patients; 40-day notification is required for the pharmacist-
in-charge.
 ♦ Controlled Substances
657 IAC Chapter 10: Electronic prescribing requirements and 
prescription transmission requirements have been updated.
 ♦ Drugs in Emergency Medical Service Programs
657 IAC Chapter 11: This newly rewritten chapter establishes 
emergency medical service drug standards and requirements.
 ♦ Electronic Data in Pharmacy Practice
657 IAC Chapter 21: Rules for electronic prescribing, electronic 
record requirements, and electronic transmission of prescrip-
tions have been updated.
 ♦ Pharmacy Internet Sites (Proposed)
657 IAC Chapter 24: This is a new chapter that establishes 
standards and minimum requirements for Internet pharmacies, 
including the National Association of Boards of Pharmacy® 
Verified Internet Pharmacy Practice Sitescm (VIPPS®) ac-
creditation.
 ♦ Iowa Prescription Monitoring Program (Proposed)
657 IAC Chapter 37: This proposed change will allow up to 
three agents of a prescriber or a pharmacist to register and 
request information from the PMP, including certified phar-
macy technicians.
 ♦ Tech-Check-Tech Programs (Proposed)
657 IAC Chapter 40: This is a new chapter that establishes 
tech-check-tech (TCT) program requirements. TCT is only 
allowed for drug delivery to institutionalized patients. Board 
approval is required 90 days prior to TCT implementation. 
Only qualified, certified pharmacy technicians may participate.
Board Calendar for 2012
The Board will hold regular Board meetings on the following 
dates (all meetings will be held at the Board office in Des Moines):
January 17-18   June 26-27
March 20-21   August 28-29
May 2-3   November 7-8
Dates are subject to change. Please contact the Board office at 
515/281-5944 to confirm meeting dates.
Follow the Board on Facebook and Twitter
Facebook ‘Iowa Board of Pharmacy’
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter  ‘IABoardPharmacy’
 http://twitter.com/#!/IABoardPharmacy
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